PolyPid Ltd. - Ordinary Shares (PYPD)
PYPD moved a median of -0.00% 30 minutes after news, and -0.69% by the close. How PYPD actually reacts to news — the realized, point-in-time move the market made, measured across 196 labeled events over the last three years with zero look-ahead.
PYPD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 147 |
| 30-min | -0.00% | 39% | 171 |
| 60-min | 0.00% | 43% | 174 |
| to close | -0.69% | 32% | 188 |
| Middle 50% of PYPD reactions | -1.11% to +1.10% |
|---|---|
| Median reaction (30-min) | -0.00% |
| Measured reactions | 196 |
Half of all PolyPid Ltd. - Ordinary Shares news events land between -1.11% and +1.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PYPD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 12 | -1.48% | 25% | -2.77% |
| Rating reiterations | 26 | -0.18% | 35% | -1.10% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how PYPD ranks against every other measured name →
That’s how PYPD usually reacts — get an email when it moves on news →Email me when PYPD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PYPD's baseline. Nothing else.
Recent PYPD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 | Press release | GlobeNewswire | +3.19% | +4.25% | |
| European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX100 | Press release | GlobeNewswire | +0.68% | +1.32% | |
| Form 6-K PolyPid Ltd. For: Oct 01 | SEC filing · Form 6-K | SEC EDGAR | +0.68% | +1.32% | |
| PolyPid Regains European Commercialization Rights for D-PLEX100, Expanding Global Commercialization Opportunities | Press release | GlobeNewswire | +0.68% | +1.32% | |
| PolyPid Announces Participation in Upcoming Fall Investor Conferences | Press release | GlobeNewswire | -0.94% | -3.01% | |
| Form 6-K PolyPid Ltd. For: Aug 12 | SEC filing · Form 6-K | SEC EDGAR | +3.92% | +5.45% | |
| Form 6-K PolyPid Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.42% | -0.42% | |
| Form S-8 PolyPid Ltd. | SEC filing · Form S-8 | SEC EDGAR | +0.42% | -0.42% | |
| PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +3.92% | +5.45% | |
| PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 | Press release | GlobeNewswire | +0.00% | +5.81% | |
| Form 6-K PolyPid Ltd. For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | +2.63% | -2.39% | |
| PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100 | Press release | GlobeNewswire | +2.63% | -2.39% | |
| Form 6-K PolyPid Ltd. For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | -13.53% | -22.73% | |
| PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada | Press release | GlobeNewswire | -13.53% | -22.73% | |
| Form 6-K PolyPid Ltd. For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | +1.45% | +0.19% | |
| Form 6-K PolyPid Ltd. For: Jun 10 | SEC filing · Form 6-K | SEC EDGAR | +0.11% | +0.44% | |
| Form 6-K PolyPid Ltd. For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | +0.64% | +7.42% | |
| PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 | Press release | GlobeNewswire | +0.64% | +7.42% | |
| PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference | Press release | GlobeNewswire | -1.25% | +0.62% | |
| Form 6-K PolyPid Ltd. For: May 13 | SEC filing · Form 6-K | SEC EDGAR | +5.62% | -2.54% | |
| PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +5.62% | -2.54% | |
| PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 | Press release | GlobeNewswire | -1.74% | -1.54% | |
| PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting | Press release | GlobeNewswire | +0.00% | -3.27% | |
| PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX100 Sustained Local Release at ESCMID Global 2026 | Press release | GlobeNewswire | -0.12% | +2.80% | |
| Form 6-K PolyPid Ltd. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.68% | -0.23% | |
| PolyPid Initiates D-PLEX100 NDA Submission to the FDA | Press release | GlobeNewswire | -0.68% | -0.23% | |
| PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX100’s New Drug Application | Press release | GlobeNewswire | -1.74% | -1.08% | |
| Form 20-F PolyPid Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -0.71% | |
| PolyPid Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +1.18% | |
| Form 6-K PolyPid Ltd. For: Feb 11 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.87% | |
| PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Press release | GlobeNewswire | +0.00% | +0.87% | |
| Form 6-K PolyPid Ltd. For: Feb 04 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.36% | |
| PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 | Press release | GlobeNewswire | -1.17% | -3.48% | |
| Form 6-K PolyPid Ltd. For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | -0.91% | -0.91% | |
| Form 6-K PolyPid Ltd. For: Dec 16 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | -1.99% | |
| PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors | Press release | GlobeNewswire | +0.25% | -1.99% | |
| Form 6-K PolyPid Ltd. For: Dec 03 | SEC filing · Form 6-K | SEC EDGAR | +1.83% | +3.39% | |
| PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission | Press release | GlobeNewswire | +1.83% | +3.39% | |
| Form 6-K PolyPid Ltd. For: Nov 26 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +3.41% | |
| PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 | Press release | GlobeNewswire | +0.00% | +0.82% | |
| Form 6-K PolyPid Ltd. For: Nov 12 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.00% | +0.00% | |
| PolyPid's D-PLEX100 Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year" | Press release | GlobeNewswire | +0.00% | +0.26% | |
| PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025 | Press release | GlobeNewswire | +0.14% | +2.43% | |
| PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress | Press release | GlobeNewswire | -0.91% | +0.76% | |
| PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference | Press release | GlobeNewswire | -1.46% | -1.46% | |
| Form 6-K PolyPid Ltd. For: Sep 16 | SEC filing · Form 6-K | SEC EDGAR | -1.42% | -2.83% | |
| PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX100 | Press release | GlobeNewswire | -1.42% | -2.83% | |
| PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference | Press release | GlobeNewswire | +1.02% | +0.00% | |
| PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference | Press release | GlobeNewswire | +1.05% | +0.59% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PYPD section they belong to.
Where else PYPD is measured.
PYPD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PolyPid Ltd. - Ordinary Shares's median reaction calculated?
Every labeled PYPD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 196 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of PYPD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PYPD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.